Literature DB >> 81414

A defect in catecholamine neurons in patients with prolactin-secreting pituitary adenoma.

G R Van Loon.   

Abstract

Although basal plasma concentrations of dopamine, noradrenaline, and adrenaline in patients with prolactin-secreting pituitary adenoma are normal, responses to oral bromocriptine are not. 1 and 2 h after bromocriptine, plasma concentrations of these three catecholamines are decreased in normal men but not in patients with hyperprolactinaemia secondary to prolactin-secreting pituitary adenoma or in normoprolactinaemic patients in whom a pituitary adenoma has been removed. Patients with prolactin-secreting pituitary adenoma probably have a defect in the regulation of brain catecholamine metabolism.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 81414     DOI: 10.1016/s0140-6736(78)91572-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

Review 1.  Hyperprolactinemia: neuroendocrine and diagnostic aspects.

Authors:  F Camanni; E Ciccarelli; E Ghigo; E E Müller
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

2.  An analysis of the effects of suicide prevention facilities on suicide rates in the United States.

Authors:  H L Miller; D W Coombs; J D Leeper; S N Barton
Journal:  Am J Public Health       Date:  1984-04       Impact factor: 9.308

3.  Nomifensine, TRH and insulin-induced hypoglycemia tests in the diagnosis of prolactinomas.

Authors:  F Iannotta; P Fachinetti; A Fachinetti; G Pinotti; L Usellini
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

4.  The management of prolactin-secreting pituitary tumors.

Authors:  S R George; G N Burrow
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

Review 5.  Control of prolactin secretion.

Authors:  G Benker; C Jaspers; G Häusler; D Reinwein
Journal:  Klin Wochenschr       Date:  1990-12-04

6.  Effect of bromocriptine on plasma catecholamines in normal subjects and prolactin-secreting tumor patients.

Authors:  A M Mancini; M Barontini; I Armando; G Levin; A Kleiman; J Razumny; I Molocznik
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

7.  Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.

Authors:  A Martinez-Campos; P Giovannini; E Parati; A Novelli; T Caraceni; E E Müller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-12       Impact factor: 10.154

Review 8.  Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications.

Authors:  E E Müller; V Locatelli; S Cella; A Peñalva; A Novelli; D Cocchi
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.